Q2 2026 revenue grew 0.8% year-over-year to $418.8 million, with adjusted EPS rising to $0.56. Specialty Surgery saw modest growth, while Tissue Reconstruction declined. Full-year guidance was updated for FX, with organic growth and adjusted EPS targets reaffirmed.Original document: Integra LifeSci…
Q2 2026 revenue grew 0.8% year-over-year to $418.8 million, with adjusted EPS rising to $0.56. Specialty Surgery saw modest growth, while Tissue Reconstruction declined. Full-year guidance was updated for FX, with organic growth and adjusted EPS targets reaffirmed.
Original document:
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.
